On May 9, 2018 Clovis Oncology, Inc. (Nasdaq: CLVS) reported that Patrick J. Mahaffy, Chief Executive Officer and President, will present at the Bank of America Merrill Lynch Healthcare Conference 2018 on Wednesday, May 16, 2018 at 11:20 AM local time (Press release, Clovis Oncology, MAY 9, 2018, View Source [SID1234526405]). The conference will be held at the Encore Hotel in Las Vegas, Nevada.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation can be accessed through the investor relations section of the Company’s website at www.clovisoncology.com. Following the live presentation, a replay of the webcast will be available on the Company’s website for 30 days.

On May 9, 2018 Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD) a clinical-stage biopharmaceutical company focused on the development of CART-cell therapies, reported that the company will present recent advances in Celyad’s pipeline at the American Society of Gene & Cell Therapy (ASGCT) (Free ASGCT Whitepaper) Annual Meeting being held May 16–19, 2018, in Chicago.

Poster presentations will highlight the recent developments of Celyad’s pipeline in autologous and allogeneic platforms to address cancers. The oral presentation will give updated data of the ongoing THINK Phase 1 trial with the case report of a CYAD-01 associated complete response in one relapsed/refractory AML patient, including observations concerning the modulation of systemic chemokines during the course of treatment.

David Gilham, VP of Research and Development at Celyad, commented: ‘Our presentations at the 2018 meeting of the ASGCT (Free ASGCT Whitepaper) will share our increasing knowledge around our lead NKG2D CAR T cell candidate along with discussing our pipeline including the B7H6 CAR T program and our allogeneic platform. These presentations are the culmination of an intensive level of activity within our R&D group. We anticipate that this will lead to a series of assets that will enter clinical stage testing during 2019.’

Presentation Details:

Title

Early Signs of Clinical Activity in AML Patients Receiving NKG2D CAR-T Cell Therapy in the Absence of Pre-Conditioning Chemotherapy: An Alternative Strategy to CAR-T Cell Therapy

Link

Number

967

Category

Cancer-Immunotherapy, Cancer Vaccines

Session

412 Advancements in T Cell-Based Therapies

Session Date & Time

Saturday, May 19, 2018, 11:00 AM CDT

Location

Continental Ballroom ABC

Posters Details:

Poster title
Functional screening of a B7H6 specific chimeric antigen receptor (CAR)

Link

Poster Number

123

Category

Cancer – Immunotherapy, Cancer Vaccines I

Session

Exhibit Hall Welcome Reception & Poster Session I

Session Date & Time

Wednesday, May 16, 2018, 5:30 PM CDT

Location

Stevens Salon C, D

Poster Title

Overcoming target-driven fratricide for CAR-T cell therapy

Link

Poster Number

119

Category

Cancer-Immunotherapy, Cancer Vaccines

Session

Exhibit Hall Welcome Reception & Poster Session I

Session Date & Time

Wednesday, May 16, 2018, 5:30 PM CDT

Location

Stevens Salon C, D

Poster Title

Expression of a TIM8 peptide reduces alloreactivity of T cells facilitating an allogeneic NKG2D Chimeric Antigen Receptor T cell therapy approach

Link

Poster Number

457

Category

Cell Therapies

Session

Exhibit Hall Networking Reception & Poster Session II

Session Date & Time

Thursday, May 17, 2018, 5:15 PM CDT

Location

Stevens Salon C, D

On May 9, 2018 Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, reported that an overview of the company’s business strategy and commercial and development-stage programs will be given at the Bank of America Merrill Lynch 2018 Health Care Conference being held at the Encore Hotel in Las Vegas, Nevada (Press release, Spectrum Pharmaceuticals, MAY 9, 2018, http://investor.sppirx.com/news-releases/news-release-details/spectrum-pharmaceuticals-present-corporate-update-bank-america-3 [SID1234526320]). The company presentation is on Wednesday, May 16, 2018, at 8:55 AM PDT.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of Spectrum’s presentation will be available at View Source

On May 9, 2018 IGEM Therapeutics (IGEM), an immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to treat cancer, reported the award of a £1.45 million grant from the UK’s innovation agency, Innovate UK (Press release, IGEM Therapeutics, MAY 9, 2018, View Source [SID1234526370]). IGEM will use the Biomedical Catalyst award to further the development of IGEM-Ch, a novel IgE antibody targeting solid tumours.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

IGEM-Ch is a novel and proprietary humanised IgE antibody that binds to the cancer antigen CSPG4 (chondroitin sulphate proteoglycan 4). The CSPG4 antigen is overexpressed in melanoma and various other cancers including triple-negative breast cancer (TNBC). Pre-clinical studies in the laboratory of Dr Sophia Karagiannis at King’s College London demonstrated that an anti-CSPG4 IgE outperformed an equivalent IgG antibody in a variety of challenging models. The company will receive £1.02M in net funding from the Biomedical Catalyst award to help progress IGEM-Ch into clinical trials by generation of a pre-clinical development package and efficient GMP manufacturing process. IGEM has issued patents covering the antibody in the US, Europe and Australia.

IGEM is building a portfolio of IgE antibodies directed against various cancer antigens including folate receptor alpha, CSPG4, HER2 and EGFR. The epsilon constant region of IgE has evolved to fight complex, multicellular parasitic organisms resident in tissue by recruiting powerful immune effector cells such as macrophages, basophils and monocytes. IGEM believes that potent immune responses arising from IgE are suited to the destruction of solid tumours which also reside in tissue. IGEM has demonstrated superior efficacy for IgE versus IgG equivalent antibodies in a range of pre-clinical cancer models. The company’s scientific founders, Dr Sophia Karagiannis, Professor James Spicer and Dr Vivienne Cox have previously transitioned the first-in-class IgE, IGEM-F, into a Phase 1 clinical trial in cancer patients.

On May 9, 2018 Protagen AG has reported the start of a collaboration with the University of California, San Francisco (UCSF) to utilize Protagen’s SeroTag technology to investigate the immuno-profiling of prostate cancer patients treated with checkpoint inhibitors and therapeutic vaccines (Press release, Protagen, MAY 9, 2018, View Source [SID1234526386]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cancer immunotherapies can be very powerful and provide novel opportunities for the treatment of cancer. However, they currently work for a limited number of indications and patients. In addition, as these therapies re-activate the immune system to fight the cancer, they sometimes can cause severe immune-related Adverse Events (irAEs). Through the collaboration, Protagen and UCSF intend to provide further insight into utilizing immune system profiling to predict treatment response and monitor prostate cancer patients for irAEs, specifically, a so-called cold tumor that it is difficult to target with immuno-therapies.

Dr. Peter Schulz-Knappe, Protagen’s Chief Scientific Officer, commented: "Our proprietary SeroTag technology has enabled patient stratification and immuno-profiling of patients into homogenous disease subgroups for several autoimmune indications. The strong link between immuno-oncology and autoimmune disease, confirmed by the observed irAEs under immunotherapy, provides us with an opportunity to improve immuno-profiling of cancer patients. We feel honored that Dr. Fong and UCSF share this view and we are excited about our collaboration, especially in an indication like prostate cancer that has shown to be difficult to target with immuno-therapies."

Dr. Lawrence Fong, the UCSF Efim Guzik Distinguished Professor in Cancer Biology and leader of the Cancer Immunotherapy Program in the UCSF Helen Diller Family Comprehensive Cancer Center added: "Although cancer immunotherapies can be effective in many different cancers, success in prostate cancer has been more limited. Nevertheless, we know that a small proportion of prostate cancer patients can respond to monotherapies. Immunologic profiling of these patients could enable approaches to patient selection. This collaboration could provide opportunities to accomplish this goal."

Disclaimer

The information stated above was prepared by Protagen AG and reflects solely the opinion of Protagen AG. Nothing in this statement shall be construed to imply any support or endorsement of Protagen AG, or any of its products, by the Regents of the University of California, its officers, agents and employees.

About UC San Francisco (UCSF)

UCSF is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. It includes top ranked graduate schools of dentistry, medicine, nursing and pharmacy; a graduate division with nationally renowned programs in basic, biomedical, transitional and population sciences; and a preeminent biomedical research enterprise.

It also includes UCSF Health, which comprises three top-ranked hospitals, UCSF Medical Center and UCSF Benioff Children’s Hospitals in San Francisco and Oakland, and other partner and affiliated hospitals and healthcare providers throughout the Bay Area.

Please visit www.ucsf.edu/news.